Janet Woodcock will be OGD* acting director following the announced departure of current director, Greg Geba. (Source: FDA Law Blog on Twitter.)
This could conceivably be a positive development for MNTA’s Copaxone ANDA insofar as Woodcock has been a close ally of MNTA dating back to the contaminated-heparin episode in 2008.
*Office of Generic Drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”